ATAI insider transaction filings
AtaiBeckley Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-09. Screen ATAI transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-09 | 4 | HERSHBERG ROBERT — Director | Option exercise (M): 48,858 @ $1.35 · Option exercise (M): 51,142 @ $1.35 · Sale (S): 100,000 @ $4.96 · Option exercise (M): 48,858 (derivative) @ $0 · Option exercise (M): 51,142 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Craig Kevin James — Chief Medical Officer | Option exercise (M): 33,051 @ $1.50 · Option exercise (M): 9,528 @ $1.18 · Sale (S): 42,579 @ $4.51 · Option exercise (M): 33,051 (derivative) @ $0 · Option exercise (M): 9,528 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Kochendoerfer Gerd — Chief Operating Officer | Option exercise (M): 50,000 @ $1.60 · Sale (S): 50,000 @ $5 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Hoffman John Francis — Director | Grant/award (A): 121,968 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Angermayer Christian — Director, 10% owner | Grant/award (A): 121,968 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Smiley Andrea Heslin — Director | Grant/award (A): 121,968 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Braunstein Scott — Director | Grant/award (A): 121,968 (derivative) @ $0 · Grant/award (A): 86,095 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Kalali Amir H — Director | Grant/award (A): 121,968 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Fischer Laurent — Director | Grant/award (A): 121,968 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | HERSHBERG ROBERT — Director | Grant/award (A): 121,968 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | JOHNSON SABRINA MARTUCCI — Director | Grant/award (A): 121,968 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Craig Kevin James — Chief Medical Officer | Option exercise (M): 27,280 @ $1.50 · Option exercise (M): 15,299 @ $1.84 · Sale (S): 42,579 @ $5 · Option exercise (M): 27,280 (derivative) @ $0 · Option exercise (M): 15,299 (derivative) @ $0 | EDGAR |
| 2026-04-10 | 4 | Angermayer Christian — Director, 10% owner Apeiron Investment Group Ltd. — 10% owner | Option exercise (M): 46,070 @ $1.88 · Option exercise (M): 410,162 @ $1.64 · Option exercise (M): 103,000 @ $1.34 · Option exercise (M): 46,070 (derivative) @ $0 · Option exercise (M): 410,162 (derivative) @ $0 · Option exercise (M): 103,000 (derivative) @ $0 | EDGAR |
| 2026-03-24 | 4 | Craig Kevin James — Chief Medical Officer | Option exercise (M): 76,224 @ $1.18 · Option exercise (M): 23,776 @ $1.50 · Sale (S): 100,000 @ $3.55 · Option exercise (M): 76,224 (derivative) @ $0 · Option exercise (M): 23,776 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | Faerm Michael E. — Chief Financial Officer | Grant/award (A): 1,275,000 (derivative) @ $0 · Grant/award (A): 285,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Barrett Christopher Ryan Cave — See remarks | Grant/award (A): 675,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Craig Kevin James — Chief Medical Officer | Grant/award (A): 675,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Short Glenn Frank — Chief Scientific Officer | Grant/award (A): 675,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Kochendoerfer Gerd — Chief Operating Officer | Grant/award (A): 675,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Johnson Anne Nagengast — Chief Financial Officer | Grant/award (A): 525,000 (derivative) @ $0 · Grant/award (A): 117,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Rao Srinivas — See remarks | Grant/award (A): 1,988,000 (derivative) @ $0 · Grant/award (A): 442,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Feilding-Mellen Cosmo — Director | Sale (S): 39,594 @ $3.90 | EDGAR |
| 2025-11-26 | 4 | Feilding-Mellen Cosmo — Director | Disposition to issuer (D): 40,400 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4 | Feilding-Mellen Cosmo — Director | Grant/award (A): 7,702,990 · Grant/award (A): 103,000 (derivative) @ $0 · Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4 | Braunstein Scott — Director | Grant/award (A): 56,818 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4 | HERSHBERG ROBERT — Director | Grant/award (A): 456,011 (derivative) @ $0 · Grant/award (A): 97,716 (derivative) @ $0 · Grant/award (A): 62,394 (derivative) @ $0 · Grant/award (A): 103,000 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Barrett Christopher Ryan Cave — See Remarks | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Apeiron Investment Group Ltd. — 10% owner Angermayer Christian — Director, 10% owner | Conversion (C): 2,367,200 · Conversion (C): 147,950 (derivative) | EDGAR |
| 2025-08-18 | 4 | Apeiron Investment Group Ltd. — 10% owner Angermayer Christian — Director, 10% owner | Purchase (P): 8,675,799 @ $2.19 | EDGAR |
| 2025-08-15 | 4 | Rao Srinivas — See Remarks | Grant/award (A): 650,794 (derivative) @ $0 · Grant/award (A): 217,777 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Hoffman John Francis — Director | Grant/award (A): 206,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Angermayer Christian — Director, 10% owner | Grant/award (A): 103,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Smiley Andrea Heslin — Director | Grant/award (A): 103,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Braunstein Scott — Director | Grant/award (A): 103,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Kalali Amir H — Director | Grant/award (A): 103,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Fischer Laurent — Director | Grant/award (A): 103,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | JOHNSON SABRINA MARTUCCI — Director | Grant/award (A): 103,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Angermayer Christian — Director, 10% owner | Grant/award (A): 131,698 (derivative) | EDGAR |
| 2025-03-24 | 4 | Kirpekar Sahil — Chief Business Officer | Sale (S): 48,563 @ $1.35 | EDGAR |
| 2025-03-24 | 4 | Craig Kevin James — Chief Medical Officer | Sale (S): 11,563 @ $1.35 | EDGAR |
| 2025-03-24 | 4 | Rao Srinivas — See Remarks | Sale (S): 75,418 @ $1.35 | EDGAR |
| 2025-03-24 | 4 | Johnson Anne Nagengast — Chief Financial Officer | Sale (S): 33,545 @ $1.35 | EDGAR |
| 2025-03-24 | 4 | Short Glenn Frank — Chief Scientific Officer | Sale (S): 13,161 @ $1.35 | EDGAR |
| 2025-03-24 | 4 | Apeiron Investment Group Ltd. — 10% owner Angermayer Christian — Director, 10% owner | Purchase (P): 1,800,000 @ $1.40 | EDGAR |
| 2025-03-19 | 4 | Craig Kevin James — Chief Medical Officer | Option exercise (M): 20,000 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-03-19 | 4 | Short Glenn Frank — Chief Scientific Officer | Option exercise (M): 32,500 · Option exercise (M): 32,500 (derivative) @ $0 | EDGAR |
| 2025-03-19 | 4 | Rao Srinivas — See Remarks | Option exercise (M): 175,000 · Option exercise (M): 175,000 (derivative) @ $0 | EDGAR |
| 2025-03-19 | 4 | Kirpekar Sahil — Chief Business Officer | Option exercise (M): 100,000 · Option exercise (M): 100,000 (derivative) | EDGAR |
| 2025-03-19 | 4 | Johnson Anne Nagengast — Chief Financial Officer | Option exercise (M): 100,000 · Option exercise (M): 100,000 (derivative) @ $0 | EDGAR |
| 2025-03-06 | 4 | Short Glenn Frank — Chief Scientific Officer | Grant/award (A): 757,915 (derivative) @ $0 | EDGAR |
Recent 8-K events — AtaiBeckley Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-03 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ATAI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →